Connect with us

Media & Technology

Carbon-Ion of C-Ion; Medicevo; the Run on Corporate Universe (OTCMKTS: COUV)

Published

on

Corporate Universe (OTCMKTS: COUV) is making a powerful run up the charts in recent days on a massive surge of volume as investors jump on board and buy up the float. COUV has transformed into a volume leader and a serious runner in small caps.

COUV has been making big moves recently acquiring two Companies including a 51% stake in Medicevo Corporation. Made using a patented production process, Medicevo’s Graphene Face Mask is scientifically proven to kill COVID-19 particles and other types of germs and infectious diseases and provides a Bacterial Filtration Efficiency (BFE) of 98% higher than N95 Masks. More recently COUV acquired Carbon ion owner of ZapGo LTD which has developed a new category of energy storage device called Carbon-Ion™ of C-Ion®. This technology charges 50x faster than lithium-ion batteries and can fully charge a cell phone in 10 seconds, and an EV in 35 seconds. Carbon owns over 3o patents. COUV also recently got all their and required disclosures to OTC Markets and the company is classified as “CURRENT”.

Corporate Universe (OTCMKTS: COUV) is a publicly traded diversified company with a focus on emerging business development to create value for our shareholders. Corporate Universe provides the environment for business growth and stability.

COUV 51% owned subsidiary Medicevo Corporation works to ensure the safety of healthcare professionals, frontline workers, and communities around the world by creating rapidly available and sustainable medical supplies. Made using a patented production process, Medicevo’s Graphene Face Mask is scientifically proven to kill COVID-19 particles and other types of germs and infectious diseases. Built with four layers of protection for the wearer, Medicevo’s Graphene Face Mask has been evaluated by the American Society for Testing and Materials standard. Medicevo’s Graphene Face Mask provides a Bacterial Filtration Efficiency (BFE) of 98% higher than N95 Masks or other face masks on the market.

More recently COUV acquired Carbon ion owner of ZapGo LTD which has developed a new category of energy storage device called Carbon-Ion™ of C-Ion®. This technology charges 50x faster than lithium-ion batteries, and radically improves the performance of supercapacitors by using high surface area carbons and ionic electrolytes. The company currently has over 30 Patents and acquires a decade of Research and Development. The company is moving to commercialization.

On December 1 COUV announced the launch and availability of its Graphene Face Mask, which is proven to filter 98% of COVID-19 particles, setting a new safety standard of Personal Protection Equipment (PPE) now available on the market.

To Find out the inside Scoop on COUV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COUV

In order to be approved by the U.S. Food and Drug Administration for use in hospitals, PPE must pass tests for flammability, differential pressure, particle filtration efficiency and bacterial filtration efficiency (BFE), and fluid resistance. Medicevo’s Graphene Face Mask has passed flammability testing and has scored a 4.2 out of 5 for differential breathability pressure. In addition, the masks scored a 98% BFE and a 96% particle filtration efficiency. The Masks have passed level two for fluid resistance.

Medicevo’s Graphene Face Mask features four layers of protection. The outer layer comprises high-quality antibacterial, non-woven fabric with strong air permeability but isolates droplets and large particles. The graphene layer and patented plating technology kill more than 99% of viruses and germs. A melt-blown cloth layer creates an isolation and dustproof effect, filtering particles less than 0.3 microns in size. Finally, a skin-friendly inner lining with honeycomb-woven fabric and adjustable ear loops stretch over the wearer’s nose and mouth to ensure a secure and airtight fit. Medicevo is the exclusive distributor of the state-of-the-art Medicevo Graphene Face Mask in the United States and Canada. The mask is available to buy now and comes in sizes for children and adults. One package of five disposable face masks retails for $39.95. Each mask is reusable for up to 15 days.

On December 16 COUV entered into an LOI to acquire Carbon Ion Energy Storage Ltd, fka ZapGo, a high technology electric battery development company, building the next generation of energy storage devices. One that is safer, faster charging, does not use rare-earth materials and can be recycled at end of life. Carbon Ion Energy Storage Ltd has acquired all the assets of ZapGo Ltd, inclusive of over 30 patents and the benefit of $25 million research and development. Currently the company has a Gen IV battery which is being prepared for commercialization.

With the advancement and acceptance of battery powered vehicles, tools, toys, appliances, personal electronics and much more the global market was estimated at over $113 Billion dollars in 2019 and will grow 3-fold over the next 5-7 years according to Grandview Research. For the past 50 years Lithium-Ion batteries have led this epic growth, even though they are challenged by battery life, charging times, heat and the potential for igniting or exploding. Carbon Ion has the solution for the next 50 years.

Isaac H. Sutton, CEO of Corporate Universe stated, “As I’ve previously told our shareholders, our goal was to identify opportunity for our shareholders, and in this transaction, I believe we have exceeded expectations and couldn’t be more excited to bring this opportunity to the market and our shareholders. Effective with the closing which is targeted before years end, Andrew will assume the CEO position, and I will become the COO. I will be focused on moving the public company expeditiously and compliantly towards a senior exchange, as Andrew and the team are focused on the business of batteries. I believe this next year will be transformative!”

For More on COUV Subscribe Right Now!

COUV is making a powerful run up the charts in recent days on a massive surge of volume as investors jump on board and buy up the float. COUV has transformed into a volume leader and a serious runner in small caps. COUV has been making big moves recently acquiring two Companies including a 51% stake in Medicevo Corporation. Made using a patented production process, Medicevo’s Graphene Face Mask is scientifically proven to kill COVID-19 particles and other types of germs and infectious diseases and provides a Bacterial Filtration Efficiency (BFE) of 98% higher than N95 Masks. More recently COUV acquired Carbon ion owner of ZapGo LTD which has developed a new category of energy storage device called Carbon-Ion™ of C-Ion®. This technology charges 50x faster than lithium-ion batteries and can fully charge a cell phone in 10 seconds, and an EV in 35 seconds. Carbon owns over 3o patents. COUV also recently got all their and required disclosures to OTC Markets and the company is classified as “CURRENT”. We will be updating on COUV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with COUV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COUV either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.